{"denoms":[{"counts":[{"groupId":"BG000","value":"222"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"122"},{"groupId":"BG003","value":"223"},{"groupId":"BG004","value":"588"}],"units":"Participants"}],"groups":[{"description":"Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor ≤ 5 cm (in maximum diameter) with negative microscopic margins are assigned to arm A: (observation only).\n\nclinical observation: Patients undergo observation\n\ntherapeutic conventional surgery: Patients undergo surgery","id":"BG000","title":"Arm A: No Adjuvant Treatment"},{"description":"Patients with high-grade tumor ≤ 5 cm (in maximum diameter) with positive microscopic margins are assigned to arm B: (adjuvant radiotherapy). Beginning between 6-42 days after surgical resection, patients undergo a total of 31 fractions of adjuvant radiotherapy.\n\nclinical observation: Patients undergo observation\n\ntherapeutic conventional surgery: Patients undergo surgery\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy","id":"BG001","title":"Arm B: Low Risk; Adjuvant Radiotherapy"},{"description":"High risk \\[metastatic, resected, incompletely resected, or unresected disease\\] patients with high-grade, grossly resected primary tumor, with metastases are assigned to receive arm C: (adjuvant chemoradiotherapy). Patients receive ifosfamide IV; doxorubicin hydrochloride IV; beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy.\n\ndoxorubicin hydrochloride: Given IV\n\nclinical observation: Patients undergo observation\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy\n\nifosfamide: Given IV","id":"BG002","title":"Arm C: Intermediate & High Risk; Adjuvant Chemoradiotherapy"},{"description":"High risk \\[metastatic, resected, incompletely resected, or unresected disease\\] patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.\n\ndoxorubicin hydrochloride: Given IV\n\nclinical observation: Patients undergo observation\n\ntherapeutic conventional surgery: Patients undergo surgery\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy\n\nifosfamide: Given IV","id":"BG003","title":"Arm D: Intermediate & High Risk; Neoadjuvant Chemoradiotherapy"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"60.88","value":"138.87"},{"groupId":"BG001","spread":"59.46","value":"142.58"},{"groupId":"BG002","spread":"69.20","value":"155.14"},{"groupId":"BG003","spread":"68.90","value":"171.31"},{"groupId":"BG004","spread":"67.10","value":"154.68"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"124"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"60"},{"groupId":"BG003","value":"120"},{"groupId":"BG004","value":"313"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"62"},{"groupId":"BG003","value":"103"},{"groupId":"BG004","value":"275"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"38"},{"groupId":"BG004","value":"90"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"185"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"95"},{"groupId":"BG003","value":"178"},{"groupId":"BG004","value":"477"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"21"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"6"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"18"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"43"},{"groupId":"BG004","value":"89"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"169"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"90"},{"groupId":"BG003","value":"137"},{"groupId":"BG004","value":"412"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"31"},{"groupId":"BG004","value":"62"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}]}